消脂清肝合剂治疗非酒精性脂肪肝的临床研究[摘要]目的观察消脂清肝合剂治疗非酒精性脂肪肝的临床疗效。方法将2012年10月~2013年7月在我院肝病门诊收治的112例非酒精性脂肪肝患者随机分为治疗组和对照组各56例。治疗组予口服消脂清肝合剂，对照组予多烯磷脂酰胆碱胶囊，疗程均为12周，观察两组患者治疗后的总有效率、肝脏B超改善情况、肝功能、血脂等指标的变化情况。结果两组治疗后肝功能指标丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）和血脂指标总胆固醇（TC）、三酰甘油（TG）均较治疗前明显下降，高密度脂蛋白胆固醇（HDL-C）明显升高，胰岛素抵抗指数（IR）明显下降，差异有统计学意义（P<0.01）；与对照组比较，治疗组治疗后IR、TG下降显著，HDL-C上升明显，差异有统计学意义（P<0.05）。肝脏B超显示，治疗组治疗后脂肪肝清除率明显高于对照组（P<0.05）；且治疗组总有效率也明显高于对照组（P<0.05）。结论消脂清肝合剂治疗非酒精性脂肪肝疗效显著，值得临床推广应用。[关键词]消脂清肝合剂；非酒精性脂肪肝；临床研究[]R259.7[文献标识码]B[]1673-9701（2014）16-0107-04ClinicalstudyofXiaozhiqingganmixtureintreatmentofnon-alcoholicfattyliverdiseaseQIANXiaoqing1ZHOU激wang1WANGXiaye1CHENGFeng21.DepartmentofGastroenterology,LishuiHospitalofTraditionalChineseMedicineinZhe激angProvince,Lishui323000,China;2.GeneralSurgeryDepartment,People'sHospitalof激angsuProvince,Nan激ng210029,China[Abstract]ObjectiveToobservetheclinicaleffectsofXiaozhiqingganmixtureintreatmentofnon-alcoholicfattyliverdisease.MethodsAtotalof112patientsofnon-alcoholicfattyliverdiseasevisitingourhospitalfromOctomber2012toJuly2013weredividedintothetreatmentgroupandthecontrolgrouprandomly,56patientsineachgroup.Forthetreatmentgroup,Xiaozhiqingganmixturewasadministratedorallywhileforthecontrolgroupweregivenpolyenephosphatidylcholinecapsulefor12weeks.Aftertreatment,thetotaleffectiverate,improvementofliverunderBultrasonic,liverfunction,andbloodlipidwereobserved.ResultsInbothgroups,theliverfunctionindicesincludingALT,AST,TCandTGweresignificantlydeclinedthanpriortreatment,HDL-Cwassignificantlyenhanced,andIRwasevidentlydecreased.Allthesedifferenceswerestatisticallysignificant(P<0.01).Comparedwiththecontrolgroup,theIRandTGofthepatientsintreatmentgroupweresignificantlydeclined,andHDL-Cwasobviouslyenhanced,bothwithstatisticalsignificance(P<0.05).AccordingtotheBultrasonicofliver,theclearanceratiooffattyliverinthetreatmentgroupwassignificantlyhigherthanthatinthecontrolgroup(P<0.05),andthetotaleffectiverateinthetreatmentgroupwasalsosignificantlyhigher(P<0.05).ConclusionXiaozhiqingganmixtureissignificantlyeffectiveintreatmentofnon-alcoholicfattyliverdiseaseandshouldbefurtherpromoted.[Keywords]XiaozhiQingganmixture;Non-alcoholicfattyliverdisease（NAFLD）;Clinicalstudy近年来，随着人们饮食结构、作息规律等的改变，非酒精性脂肪肝（NAFLD）的发病率呈逐年上升趋势。世界范围内的流行病学统计结果显示，NAFLD的发病率约占总人口的8%左右，我国约为10%~15%[1]。相对于肝脏恶性肿瘤性疾病或严重的占位性病变而言，NAFLD是一种病理程度较轻的肝脏良性病变，早期对肝功能的损害速度和程度较为轻微。但随着病情的发展，大量脂肪细胞堆积于肝脏后，可导致患者的肝脏细胞出现代谢异常、凋亡等现象，对肝功能的损害程度也随着增加。临床研究证实，NAFLD若长期发展而不加以治疗，约31%的患者可发展为肝硬化、肝脏纤维化等，对患者的生命健康将产生极为严重的负面影响[2]。在NAFLD的临床治疗方面，以降脂、保肝药物的使用较为普遍，且用药周期较长。因NAFLD为慢性代谢性疾病，其早期除药物治疗以外，尚无有效手段。西药在NAFLD的治疗方面具有高效、快速的优点，但长期使用毒副作用...